Table of Contents Author Guidelines Submit a Manuscript

The Role of Invasive Procedures in Lung Cancer Staging

Call for Papers

Treatment of lung cancer is strictly based on an accurate staging. Although surgery still remains the best cure for lung cancer, it can be offered only in early stages of the disease. Mediastinal staging and diagnosis of the primary tumor should be performed in order to plan surgery or alternative treatment. Molecular characterization, added to histology of the tumor, nowadays, is able to extend the possibility of cure either postoperatively or when surgery is not indicated. Also failure of chemotherapy lines often requires a new characterization of the tumor. Introduction of immunotherapy makes it important to look for new biomarkers, though it becomes more and more important to obtain tissue from the tumor and/or tumor environment.

The main challenges that thoracic surgeons and oncologists are facing nowadays are how far we can push an invasive procedure for lung cancer staging and which is the most indicative invasive procedure for mediastinal and/or main tumor and metastases characterization. The second goal of new procedures is to obtain accurate tissue during and after modern regiments of treatment (restaging).

The aim of this special issue is to attract papers dealing with invasive staging of lung cancer such as Endobronchial Ultrasound (EBUS) through bronchoscopy and esophagoscopy (separately EBUS, EUS, or both in one procedure), videothoracoscopy (VATS), and robotic surgery. The question is if currently there is a place for mediastinoscopy, mediastinotomy, thoracotomy, and other related surgical procedure aimed at characterizing lung cancer metastases. TEMLA is of interest and may be presented as diagnostic/curable method.

Potential topics include but are not limited to the following:

  • Invasive preoperative lymph node characterization in lung cancer
  • VATS procedure for lung cancer staging
  • Robotic procedure for lung cancer staging
  • Thoracotomy for primary tumor and/or lymph node characterization
  • Recharacterization of lung cancer during chemotherapy and immunotherapy
  • Surgical biopsy for molecular characterization in lung cancer
  • Evaluation of biomarkers for immunotherapy in small biopsy
  • Surgical characterization of lung cancer metastases
  • Value of primary tumor and metastases samples: point of view of pathologist
  • Troubles in accurate diagnosis of histological subtypes of lung cancer: point of view of pathologist

Authors can submit their manuscripts through the Manuscript Tracking System at https://mts.hindawi.com/submit/journals/bmri/pulmonology/iplc/.

Submission DeadlineFriday, 13 July 2018
Publication DateNovember 2018

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

Guest Editors